NVO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Novo Nordisk is not a strong buy for a beginner investor seeking long-term growth at this time. While the company has shown modest financial growth, the technical indicators and analyst sentiment suggest caution. The lack of significant positive catalysts, combined with bearish technical trends and competitive pressures in the GLP-1 drug market, make it prudent to hold off on investing for now.
The stock's MACD is positive but contracting, RSI is neutral, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 36.35, with resistance at 37.549. Overall, the technical indicators suggest a bearish trend.
Hedge funds are increasing their positions significantly, and Novo Nordisk has appointed Mars CEO Poul Weihrauch as a board observer to strengthen its obesity drug market strategy.
Analysts have downgraded the stock, citing concerns about underperformance in the U.S. weight loss drug market, disappointing trial results, and potential margin contraction due to patent expiration. Competitors like Eli Lilly are showing strong growth in the GLP-1 market, posing a significant challenge.
In Q4 2025, revenue increased by 0.69% YoY, net income rose by 3.84% YoY, and EPS grew by 3.30% YoY. However, gross margin dropped by 4.65% YoY, indicating potential cost pressures.
Analysts are cautious, with multiple downgrades and reduced price targets. Bernstein initiated coverage with an Underperform rating, citing a lack of catalysts and concerns about U.S. market performance. Other firms like HSBC, TD Cowen, and Goldman Sachs have also lowered price targets and ratings, reflecting a bearish sentiment.
